Immediate Impact
2 from Science/Nature 68 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Works of Serdar Şıvgın being referenced
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
2018
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Serdar Şıvgın | 390 | 343 | 124 | 131 | 56 | 742 | |
| Nilgün Sayınalp | 488 | 191 | 130 | 137 | 81 | 843 | |
| Yi‐Kong Keung | 371 | 193 | 108 | 98 | 55 | 804 | |
| Michael J. Dugan | 492 | 214 | 241 | 175 | 41 | 851 | |
| B. A. McVerry | 374 | 185 | 73 | 85 | 46 | 777 | |
| Vassilios Perifanis | 405 | 408 | 144 | 94 | 54 | 778 | |
| Mehmet Turgut | 455 | 189 | 197 | 100 | 58 | 794 | |
| H. Bartels | 346 | 249 | 200 | 140 | 42 | 908 | |
| Orly Leiva | 195 | 226 | 117 | 147 | 69 | 830 | |
| Nicholas Wickham | 289 | 172 | 130 | 257 | 34 | 795 | |
| J.-M. Boiron | 410 | 175 | 126 | 113 | 32 | 698 |
All Works
Loading papers...